The Manufacturers Life Insurance Company Makes New $1.96 Million Investment in DENTSPLY SIRONA Inc. $XRAY

The Manufacturers Life Insurance Company purchased a new stake in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) during the 2nd quarter, Holdings Channel.com reports. The fund purchased 184,321 shares of the medical instruments supplier’s stock, valued at approximately $1,956,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of XRAY. Daiwa Securities Group Inc. lifted its holdings in DENTSPLY SIRONA by 2.9% in the fourth quarter. Daiwa Securities Group Inc. now owns 26,814 shares of the medical instruments supplier’s stock valued at $306,000 after acquiring an additional 767 shares during the period. Blue Trust Inc. grew its stake in shares of DENTSPLY SIRONA by 10.8% during the 1st quarter. Blue Trust Inc. now owns 12,555 shares of the medical instruments supplier’s stock valued at $146,000 after purchasing an additional 1,226 shares during the period. Oregon Public Employees Retirement Fund grew its stake in shares of DENTSPLY SIRONA by 3.3% during the 1st quarter. Oregon Public Employees Retirement Fund now owns 40,944 shares of the medical instruments supplier’s stock valued at $475,000 after purchasing an additional 1,300 shares during the period. Empowered Funds LLC increased its position in shares of DENTSPLY SIRONA by 8.8% during the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after purchasing an additional 1,320 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB lifted its stake in shares of DENTSPLY SIRONA by 13.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 13,055 shares of the medical instruments supplier’s stock worth $149,000 after purchasing an additional 1,500 shares during the period. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on XRAY. Barrington Research set a $15.00 price objective on shares of DENTSPLY SIRONA in a report on Monday, August 10th. UBS Group cut their price target on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research note on Monday, August 3rd. Barclays raised their price target on DENTSPLY SIRONA from $9.00 to $11.00 and gave the company an “underweight” rating in a report on Monday, August 24th. Finally, BMO Capital Markets reaffirmed a “market perform” rating and set a $13.00 price objective on shares of DENTSPLY SIRONA in a report on Friday, August 7th. Three investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, DENTSPLY SIRONA presently has an average rating of “Hold” and an average target price of $13.54.

DENTSPLY SIRONA Stock Up 1.2%

Shares of NASDAQ XRAY opened at $11.43 on Friday. The company has a current ratio of 1.63, a quick ratio of 1.07 and a debt-to-equity ratio of 1.48. DENTSPLY SIRONA Inc. has a 12-month low of $9.40 and a 12-month high of $14.86. The firm’s 50-day moving average price is $12.16 and its 200-day moving average price is $11.67. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of -4.16, a P/E/G ratio of 1.44 and a beta of 0.84.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, topping the consensus estimate of $0.35 by $0.17. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%.The company had revenue of $898.00 million during the quarter, compared to analyst estimates of $889.93 million. During the same quarter last year, the business posted $0.52 earnings per share. The firm’s revenue was down 4.1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, equities research analysts anticipate that DENTSPLY SIRONA Inc. will post 1.4 EPS for the current fiscal year.

Insider Transactions at DENTSPLY SIRONA

In related news, Director Brian T. Gladden purchased 9,985 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were bought at an average price of $10.02 per share, for a total transaction of $100,049.70. Following the acquisition, the director owned 61,849 shares of the company’s stock, valued at approximately $619,726.98. This represents a 19.25% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Brian P. Mckeon purchased 10,000 shares of the stock in a transaction that occurred on Friday, June 12th. The stock was bought at an average price of $10.12 per share, with a total value of $101,200.00. Following the completion of the transaction, the director owned 10,000 shares of the company’s stock, valued at $101,200. The trade was a ? increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders purchased 35,160 shares of company stock worth $351,179. 0.46% of the stock is currently owned by company insiders.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.